Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence

Annals of Intensive Care

Table 3 Cefiderocol dosing recommendations

	Dosing recommendation
Creatinine clearance, mL/min^a
≥ 120	2 g, every 6 h, infused over 3 h
90–120	2 g, every 8 h, infused over 3 h
60–90	2 g, every 8 h, infused over 3 h
30–59	1.5 g, every 8 h, infused over 3 h
15–29	1 g, every 8 h, infused over 3 h
< 15 (with or without intermittent hemodialysis^b)	0.75 g, every 12 h, infused over 3 h
CRRT^c—effluent flow rate^d, L/h
≥ 4.1	2 g, every 8 h, infused over 3 h
3.1–4	1.5 g, every 8 h, infused over 3 h
2.1–3	2 g, every 12 h, infused over 3 h
≤ 2	1.5 g, every 12 h, infused over 3 h

Adapted from [49]
^aCreatinine clearance estimated by Cockcroft–Gault formula
^bCefiderocol is removed by hemodialysis; cefiderocol dose should be administered immediately after hemodialysis for patients who require intermittent hemodialysis
^cIncludes patients receiving continuous venovenous hemofiltration, continuous venovenous hemodialysis, continuous venovenous hemodiafiltration
^dUltrafiltrate flow rate for continuous venovenous hemofiltration, dialysis flow rate for continuous venovenous hemodialysis, ultrafiltrate flow rate plus dialysis flow rate for continuous venovenous hemodiafiltration
CRRT continuous renal replacement therapy